10-K: Seres Therapeutics Navigates Post-VOWST Sale, Focuses on SER-155 Development

Seres Therapeutics details its financial position and strategic shift following the sale of its VOWST business, emphasizing the development of SER-155 and other live biotherapeutic candidates.

Summary

• Seres Therapeutics is now focused on developing SER-155, an oral live biotherapeutic, after selling its VOWST business to Nestl Health Science in September 2024.
• A Phase 1b study of SER-155 showed a significant reduction in bloodstream infections and antibiotic use in allo-HSCT patients.
• The FDA granted Breakthrough Therapy designation to SER-155 in December 2024.
• The company is designing a Phase 2 study for SER-155, potentially as part of a Phase 2/3 seamless design, with FDA feedback incorporated.
• Seres plans to submit the draft protocol to the FDA in the second quarter of 2025.
• The sale of the VOWST business included $100 million upfront, a $50 million installment received in January 2025, a $25 million installment due in July 2025, and a prepaid milestone of $60 million.
• Future milestone payments tied to VOWST sales could reach $275 million.
• Seres and Nestl share profits/losses from VOWST sales until December 31, 2025.
• As of December 31, 2024, Seres had cash and cash equivalents of $30.8 million.
• The company anticipates needing additional funding in the first quarter of 2026.
• There is substantial doubt about Seres' ability to continue as a going concern.
• The net loss from continuing operations for 2024 was $125.8 million.
• As of December 31, 2024, Seres had net operating loss carryforwards of $580.1 million for federal income tax purposes and $543.6 million for state income tax purposes.
• The company received a notice from Nasdaq in November 2024 regarding failure to meet the minimum bid price requirement.
• Seres intends to seek stockholder approval for a reverse stock split at the 2025 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments regarding SER-155 and the sale of VOWST, the company's financial situation and Nasdaq compliance issues raise concerns.

Positives

• SER-155 has shown promising results in reducing bloodstream infections and antibiotic use.
• The FDA has granted Breakthrough Therapy designation to SER-155.
• The company has received FDA feedback on the development strategy for SER-155.
• The sale of the VOWST business provides capital to advance SER-155 and other pipeline candidates.
• SPN purchased 14,285,715 shares of Seres' common stock at $1.05 per share, for an aggregate purchase price of $15 million.

Negatives

• Seres has incurred significant operating losses and expects to continue to do so.
• There is substantial doubt about Seres' ability to continue as a going concern.
• The company is dependent on the success of SER-155 and other early-stage product candidates.
• Seres received a Nasdaq notice regarding failure to meet the minimum bid price requirement.
• The total amount of the Second Installment Payment and Milestone Payments we may receive from the Transaction, and the amounts payable or due under the Profit Sharing Payments, are subject to various risks and uncertainties.

Risks

• The company needs additional funding to advance its product candidates.
• Clinical drug development is a risky, lengthy, and expensive process.
• Delays in patient enrollment could impact regulatory approvals.
• Product candidates may fail to achieve market acceptance.
• Seres faces substantial competition in the biopharmaceutical industry.
• The company's ability to use net operating loss carryforwards may be limited.
• The price of Seres' common stock may be volatile.

Future Outlook

Seres intends to focus on progressing the development of SER-155 and maximizing the opportunity of live biotherapeutics utilizing its differentiated drug discovery, development and manufacturing platforms and capabilities. The company anticipates needing additional funding in the first quarter of 2026.

Management Comments

• The company is progressing the development of SER-155, an investigational, oral, live biotherapeutic designed to decolonize GI pathogens, improve epithelial barrier integrity, and regulate immune response to prevent bacterial BSIs as well as other pathogen-associated negative clinical outcomes in patients undergoing allo-HSCT.
• The company plans to submit the draft protocol to the FDA in the second quarter of 2025 to obtain further feedback.
• The company believes that the scientific and clinical data from the development of VOWST and the data from the SER-155 Phase 1b study validate this novel therapeutic approach in the context of infection.
• The company believes this approach may be replicable across different bacterial pathogens to develop live biotherapeutics with the potential to protect a range of medically compromised patients from infections, including pathogens that harbor AMR.

Industry Context

The announcement reflects the growing interest in microbiome-based therapeutics and the challenges faced by companies in this emerging field, including the need for significant capital investment and navigating regulatory pathways.

Comparison to Industry Standards

• The 77% relative risk reduction in bloodstream infections observed in the SER-155 Phase 1b study is a notable result, potentially positioning it as a competitive therapy in the allo-HSCT setting.
• Companies like Vedanta Biosciences and Finch Therapeutics are also developing microbiome-based therapies, but SER-155's focus on infection prevention in allo-HSCT patients differentiates it.
• The sale of VOWST to Nestl Health Science is similar to other acquisitions in the microbiome space, such as Takeda's acquisition of Finch Therapeutics' inflammatory bowel disease program.
• The company's decision to focus on SER-155 and other cultivated live biotherapeutic candidates is a strategic shift, similar to other companies that have narrowed their focus to core assets after acquisitions or strategic realignments.

Legal Proceedings

• Vedanta Biosciences, Inc. and The University of Tokyo filed a complaint against Seres and Nestl alleging that the making, sale and use of VOWST infringes on U.S. Patents.

Related Party Transactions

• The sale of the VOWST business to Nestl Health Science.
• The securities purchase agreement with SPN.
• The transition services agreement with NESA.
• The cross-license agreement with SPN.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of a reverse stock split.
• Employees may experience job insecurity due to the company's financial situation.
• Patients may benefit from the development of SER-155 and other live biotherapeutic candidates.
• Suppliers and creditors face the risk of delayed or reduced payments if the company's financial situation worsens.

Next Steps

• Design and conduct a Phase 2 study for SER-155.
• Submit the draft protocol to the FDA in the second quarter of 2025.
• Seek stockholder approval for a reverse stock split at the 2025 Annual Meeting of Stockholders.
• Secure additional funding to support ongoing operations.

Key Dates